Abstract
Serratia marcescens is a Gram-negative bacterium that mostly causes urinary tract infections, respiratory infections, and catheter-related bloodstream infections. It rarely causes pericarditis, especially leading to tamponade, which is exceptionally rare. We describe a case that had a history of intravenous drug usage and presented with dyspnea and chest pain. Small cell lung carcinoma and a newly developed moderate pericardial effusion with echocardiographic indications of imminent tamponade were discovered during imaging. Pericardial fluid cultures identified Serratia marcescens. The patient was treated successfully with pericardial fluid drainage followed by antibiotics. This case emphasizes the importance of considering unusual organisms like S. marcescens when treating pericardial infections, particularly in patients who are at high risk. Early identification and focused treatment are crucial for the management of complications like cardiac tamponade.
Keywords: cardiac tamponade, iv drug-use, serratia, serratia marcescens pericarditis, small-cell lung carcinoma
Introduction
Serratia marcescens is a Gram-negative, facultative anaerobic bacterium that is an opportunistic pathogen causing various healthcare-associated infections [1], including urinary, respiratory, and catheter-related infections, especially in immunocompromised and intravenous drug users [2,3]. Cardiac involvement is rare; when it occurs, it most commonly presents as infective endocarditis, accounting for a small fraction of all endocarditis cases (e.g., Serratia caused 14% of all addict-associated endocarditis) [4]. Serratia pericarditis is exceptionally rare, with one reported case in 1983. [5]. We report a rare case of pericarditis caused by Serratia marcescens, leading to cardiac tamponade. This article was previously presented as a poster at the 2025 Society of Hospital Medicine Converge Meeting on April 24, 2025.
Case presentation
A 66-year-old male with a history of intravenous (IV) drug use presented with a day history of acute onset chest pain and shortness of breath. The physical exam was unremarkable. Toxicology screen identified cocaine, cannabinoids, and fentanyl. X-ray showed a hilar mass, which on CT showed a right upper lobe nodule concerning for malignancy and mediastinal and hilar adenopathy. EKG showed diffuse non-specific ST-elevations. A urine culture revealed significant colonies of Klebsiella pneumoniae. The patient was started on trimethoprim-sulfamethoxazole. Bronchoscopic biopsy was subsequently performed, which showed small cell lung cancer and Actinomyces in lung culture. Initially absent on the first CT, follow-up CT 2 days later for staging revealed a previously undetected moderate pericardial effusion, as shown in Figure 1. Although the exam demonstrated no paradoxical pulse or tachycardia, the echocardiography showed pericardial effusion, as shown in Figure 2, and mitral transvalvular velocity variation during respiration, suggesting cardiac tamponade, as shown in Figure 3. However, it did not show any evidence of vegetations. The patient had a pericardial window done, and 300 ml of pericardial fluid was initially removed. The pericardial fluid culture was positive for Serratia marcescens, which was subsequently managed with piperacillin-tazobactam 4.5 g 8 hourly. However, blood cultures, which were negative on admission, remained so on re-culture. Pericardial biopsy did not reveal any malignancy. He started chemotherapy and was later discharged on piperacillin-tazobactam to complete 6 weeks of therapy.
Figure 1. Contrast-enhanced axial CT scan demonstrating pericardial effusion.
The measurement marker indicates pericardial fluid thickness of approximately 19.5 mm.
Figure 2. Transthoracic echocardiogram (parasternal long-axis view) showing pericardial effusion.
The measurement markers demonstrate a pericardial fluid collection of approximately 1.17 cm.
Figure 3. Transthoracic echocardiography with pulsed-wave Doppler across mitral inflow in apical four-chamber view demonstrating increased mitral transvalvular velocity variation during respiration, suggestive of cardiac tamponade.
The marked arrows show peak velocity of 110 cm/s (5 mmHg gradient) during inspiration and 84.8 cm/s (3 mmHg gradient) during expiration, showing increased respiratory variation in mitral inflow velocities, which is suggestive of tamponade physiology.
Discussion
S. marcescens is a facultative Gram-negative bacillus that causes a wide spectrum of infections, including those involving the urinary tract, respiratory system, biliary tree, and catheter-associated sites [1]. However, its involvement in pericardial disease is exceptionally rare, especially in the absence of bacteremia or endocarditis. Bacterial pericarditis itself is uncommon, with Streptococcus pneumoniae and Staphylococcus aureus being the most frequent organisms [6,7]. Endocarditis is often observed when the heart is involved, but isolated pericarditis, particularly due to S. marcescens, is exceedingly rare. Our literature review revealed only one reported case of pericarditis due to S. marcescens, with the patient having disseminated infection and bacteremia [5]. Isolated pericarditis due to S. marcescens was not found during our review. This highlights the need to consider rare pathogens like S. marcescens in pericardial effusion, especially in patients with known risk factors.
Acute pericarditis in the developed world is usually idiopathic or of viral origin, and large effusions are generally linked to malignancy, tuberculosis, hypothyroidism, or are idiopathic [8]. In our case, although the patient had a history of lung cancer, both pericardial biopsy and cytology were negative for malignant involvement. Furthermore, there were no signs of common precipitating causes, such as blunt trauma, aortic dissection, or cardiac rupture. Given this, an infectious etiology was suspected.
Notably, the patient had a history of intravenous drug use (IVDU), a recognized risk factor for Serratia infections [3]. While IVDU typically predisposes individuals to bacteremia or endocarditis, our case reinforces that localized infections such as pericarditis can occur independently.
S. marcescens is known for its complex antibiotic resistance mechanisms. It often expresses inducible AmpC and extended-spectrum beta-lactamase (ESBLs), making it resistant to several classes of antibiotics, including penicillins and cephalosporins [1,9]. While carbapenems have traditionally been the first-line agents for Serratia infections, rising resistance to carbapenems is concerning [10]. Recent studies suggest that alternatives such as piperacillin-tazobactam or fourth-generation cephalosporins can be used effectively, especially in non-ESBL-producing strains. In our case, piperacillin-tazobactam was used successfully. This aligns with recent findings advocating for carbapenem-sparing approaches where susceptibility permits. [11] Nevertheless, the challenge in treating Serratia infections lies not only in drug resistance but also in the organism’s ability to evade host defenses through biofilm formation and latent persistence [1].
There have been reported instances of S. marcescens recurrence despite apparent resolution, even after prolonged periods. One patient experienced recurrent implantable cardioverter-defibrillator (ICD) infections, while another developed pericardial effusion post-cardiac transplant and later presented with sternal osteitis caused by the same organism 15 years later [12,13]. These cases underscore Serratia’s potential for long-term latency and recurrence, highlighting the need for prolonged monitoring even after apparent clinical recovery.
Given its aggressive nature, rapid progression, and high mortality, early diagnosis and timely initiation of targeted antibiotics are paramount in bacterial pericarditis [5,7]. Clinicians should maintain a high index of suspicion in at-risk populations who present with large or rapidly accumulating pericardial effusions.
Conclusions
This case illustrates the possibility of Serratia pericarditis as a cause of rapidly growing pericardial effusion. Risk factors such as IV drug use should raise suspicion toward the diagnosis of infectious etiology. Early diagnosis and treatment are crucial to prevent complications such as cardiac tamponade.
Disclosures
Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study.
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:
Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.
Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.
Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Author Contributions
Concept and design: Ashirbad Acharya, Anurag Karki, Ricardo Conti
Acquisition, analysis, or interpretation of data: Ashirbad Acharya, Yogesh Pandey, Puja Thapa, Narayan Bhurtel, Simran Pradhan, Suraj Shrestha
Drafting of the manuscript: Ashirbad Acharya, Anurag Karki, Ricardo Conti, Narayan Bhurtel, Simran Pradhan, Suraj Shrestha
Critical review of the manuscript for important intellectual content: Ashirbad Acharya, Anurag Karki, Ricardo Conti, Yogesh Pandey, Puja Thapa
Supervision: Ashirbad Acharya, Ricardo Conti
References
- 1.Serratia marcescens. Hejazi A, Falkiner FR. https://pubmed.ncbi.nlm.nih.gov/9368530/ J Med Microbiol. 1997;46:903–912. doi: 10.1099/00222615-46-11-903. [DOI] [PubMed] [Google Scholar]
- 2.Risk factors for mortality in patients with Serratia marcescens bacteremia. Kim SB, Jeon YD, Kim JH, et al. https://pubmed.ncbi.nlm.nih.gov/25683980/ Yonsei Med J. 2015;56:348–354. doi: 10.3349/ymj.2015.56.2.348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Intravenous drug use: A significant risk factor for Serratia bacteremia. McCann T, Elabd H, Blatt SP, Brandt DM. https://pubmed.ncbi.nlm.nih.gov/35222998/ Ther Adv Infect Dis. 2022;9 doi: 10.1177/20499361221078116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Serratia marcescens endocarditis: A regional illness associated with intravenous drug abuse. Mills J, Drew D. https://pubmed.ncbi.nlm.nih.gov/1106290/ Ann Intern Med. 1976;84:29–35. doi: 10.7326/0003-4819-84-1-29. [DOI] [PubMed] [Google Scholar]
- 5.Subacute constrictive pericarditis from Serratia marcescens bacteremia. Khan MY. https://pubmed.ncbi.nlm.nih.gov/6357992/ Hum Pathol. 1983;14:1089–1091. doi: 10.1016/s0046-8177(83)80268-8. [DOI] [PubMed] [Google Scholar]
- 6.A rare case of primary purulent pericarditis caused by Streptococcus constellatus. Kapačinskaitė M, Gabartaitė D, Šatrauskienė A, Sakaitė I, Maneikienė VV, Zorinas A, Janušauskas V. https://pubmed.ncbi.nlm.nih.gov/36676783/ Medicina (Kaunas) 2023;59:159. doi: 10.3390/medicina59010159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Primary acute pericardial disease: a prospective series of 231 consecutive patients. Permanyer-Miralda G, Sagristá-Sauleda J, Soler-Soler J. https://pubmed.ncbi.nlm.nih.gov/4050698/ Am J Cardiol. 1985;56:623–630. doi: 10.1016/0002-9149(85)91023-9. [DOI] [PubMed] [Google Scholar]
- 8.2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS) Adler Y, Charron P, Imazio M, et al. https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Pericardial-Diseases-Guidelines-on-the-Diagnosis-and-Management-of. Eur Heart J. 2015;36:2921–2964. doi: 10.1093/eurheartj/ehv318. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Antimicrobial treatment of Serratia marcescens invasive infections: Systematic review. Zivkovic Zaric R, Zaric M, Sekulic M, et al. Antibiotics (Basel) 2023;12:367. doi: 10.3390/antibiotics12020367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Current epidemiological status and antibiotic resistance profile of Serratia marcescens. Cosimato I, Santella B, Rufolo S, et al. Antibiotics (Basel) 2024;13:323. doi: 10.3390/antibiotics13040323. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.An antimicrobial treatment assessment of Serratia marcescens bacteremia and endocarditis. Slain D, Howard C, Cooper CG. https://pubmed.ncbi.nlm.nih.gov/39816409/ Front Antibiot. 2022;1:942721. doi: 10.3389/frabi.2022.942721. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Serratia marcescens: A rare cause of recurrent implantable cardioverter defibrillator site infection. Hawkey S, Choy A. https://pubmed.ncbi.nlm.nih.gov/26605092/ Case Rep Cardiol. 2015;2015:641297. doi: 10.1155/2015/641297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Relapse of Serratia marcescens sternal osteitis 15 years after the first episode. Paquin A, Lepelletier D, Leprince C, et al. https://pubmed.ncbi.nlm.nih.gov/22090399/ J Clin Microbiol. 2012;50:184–186. doi: 10.1128/JCM.01327-11. [DOI] [PMC free article] [PubMed] [Google Scholar]



